Progenitor cells from cartilage—No osteoarthritis‐grade‐specific differences in stem cell marker expression

Bernstein, Peter S.; Sperling, Ines; Corbeil, Denis; Hempel, Ute; Fickert, Stefan

doi:10.1002/btpr.1668

Cited by 26 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 Cells with phenotypic and functional properties similar to mesenchymal stem cell or progenitor cell populations, such as those derived from bone marrow, have been detected mostly in the superficial zone of mature articular cartilage (Figure 2a). 28,29,46,47 These cells were characterized by the expression of surface markers, including CD105, 28,48,49 vascular cell adhesion protein 1 (VCAM-1, also known as CD106), 26,30 CD166, 8,28,48 Notch 1, 9,30,36 STRO-1 9,30,43 and smooth-muscle actin. 50 For example, Lotz et al .…”

Section: Origin Of Cspcsmentioning

confidence: 99%

Origin and function of cartilage stem/progenitor cells in osteoarthritis

2014

View full text Add to dashboard Cite

Articular cartilage is a physiologically non-self-renewing avascular tissue with a singular cell type, the chondrocyte, which functions as the load-bearing surface of the arthrodial joint. Injury to cartilage often progresses spatiotemporally from the articular surface to the subchondral bone, leading to development of degenerative joint diseases such as osteoarthritis (OA). Although lacking intrinsic reparative ability, articular cartilage has been shown to contain a population of stem cells or progenitor cells, similar to those found in many other adult tissues, that are thought to be involved in the maintenance of tissue homeostasis. These so-called cartilage-derived stem/progenitor cells (CSPCs) have been observed in human, equine and bovine articular cartilage, and have been identified, isolated and characterized on the basis of expression of stem-cell-related surface markers, clonogenicity and multilineage differentiation ability. However, the origin and functions of CSPCs are incompletely understood. We review here the current status of CSPC research and discuss the possible origin of these cells, what role they might have in cartilage repair, and their therapeutic potential in OA.

show abstract

Section: Origin Of Cspcsmentioning

confidence: 99%

Origin and function of cartilage stem/progenitor cells in osteoarthritis

2014

View full text Add to dashboard Cite

show abstract

“…These authors compared normal cartilage tissue obtained from donors with no known history of joint disease to tissue obtained from patients who had undergone total joint replacement surgery [ 22 , 26 ]. In contrast, our study compared different degrees of morphological OA-related damaged tissues, which may provide insight as to when MPC cells are most abundant in relation to OA progression similar to a previous study [ 46 ]. Differing with our study, sample grading was done according to Outerbridge’s classification and not confirmed histologically.…”

Section: Discussionmentioning

confidence: 83%

“…Differing with our study, sample grading was done according to Outerbridge’s classification and not confirmed histologically. Cells isolated from OA cartilage at the third passage expressed 50–70% of MSC markers CD9 + CD105 + CD73 + irrespective of the stage of the original cartilage degradation [ 46 ]. The cells were collected at third passage whereas ours were collected at second passage and this could effect cell phenotypic expression [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Progenitor Cells from Cartilage: Grade Specific Differences in Stem Cell Marker Expression

Mazor

Césaro

Ali

et al. 2017

IJMS

View full text Add to dashboard Cite

Recent research has confirmed the presence of Mesenchymal stem cell (MSC)-like progenitors (MPC) in both normal and osteoarthritic cartilage. However, there is only limited information concerning how MPC markers are expressed with osteoarthritis (OA) progression. The purpose of this study was to compare the prevalence of various MPC markers in different OA grades. Human osteoarthritic tibial plateaus were obtained from ten patients undergoing total knee replacement. Each sample had been classified into a mild or severe group according to OARSI scoring. Tissue was taken from each specimen and mRNA expression levels of CD105, CD166, Notch 1, Sox9, Acan and Col II A1 were measured at day 0 and day 14 (2 weeks in vitro). Furthermore, MSC markers: Nucleostemin, CD90, CD73, CD166, CD105 and Notch 1 were studied by immunofluorescence. mRNA levels of MSC markers did not differ between mild and severe OA at day 0. At day 14, protein analysis showed that proliferated cells from both sources expressed all 6 MSC markers. Only cells from the mild OA subjects resulted in a significant increase of mRNA CD105 and CD166 after in vitro expansion. Moreover, cells from the mild OA subjects showed significantly higher levels of CD105, Sox9 and Acan compared with those from severe OA specimens. Results confirmed the presence of MSC markers in mild and severe OA tissue at both mRNA and protein levels. We found significant differences between cells obtained from mild compared to severe OA specimens suggests that mild OA derived cells may have a greater MSC potential.

show abstract

“…Interestingly, MSCs are able to differentiate into both mesenchymal and nonmesenchymal lineages, as these cells retain multilineage potential. According to the work of Dominici and to The International Society of Cellular Therapy (http://www.celltherapysociety.org/), MSCs are defined by the following minimal set of criteria: (1) capacity to grow in adherence to plastic surface of dishes when maintained in standard culture conditions; (2) to express cytospecific cell surface markers, that is, CD105, CD90, and CD73, to be negative for other cell surface markers, that is, CD45, CD34, CD14, and CD11b; (3) capacity to differentiate into mesenchymal lineages, under appropriate in vitro conditions [52, 53]. However, further review on their definition and origin is needed in the light of recent observations [54, 55].…”

Section: Adult Stem Cell Typesmentioning

confidence: 99%

Perspectives on the Use of Stem Cells for Autism Treatment

Siniscalco

Bradstreet²,

Sych³

et al. 2013

Stem Cells International

View full text Add to dashboard Cite

Autism and autism spectrum disorders (ASDs) are complex neurodevelopmental disorders. ASDs are clinically defined by deficits in communication, social skills, and repetitive and/or restrictive interests and behaviours. With the prevalence rates for ASDs rapidly increasing, the need for effective therapies for autism is a priority for biomedical research. Currently available medications do not target the core symptoms, can have markedly adverse side-effects, and are mainly palliative for negative behaviours. The development of molecular and regenerative interventions is progressing rapidly, and medicine holds great expectations for stem cell therapies. Cells could be designed to target the observed molecular mechanisms of ASDs, that is, abnormal neurotransmitter regulation, activated microglia, mitochondrial dysfunction, blood-brain barrier disruptions, and chronic intestinal inflammation. Presently, the paracrine, secretome, and immunomodulatory effects of stem cells would appear to be the likely mechanisms of application for ASD therapeutics. This review will focus on the potential use of the various types of stem cells: embryonic, induced pluripotential, fetal, and adult stem cells as targets for ASD therapeutics.

show abstract

Progenitor cells from cartilage—No osteoarthritis‐grade‐specific differences in stem cell marker expression

Cited by 26 publications

References 32 publications

Origin and function of cartilage stem/progenitor cells in osteoarthritis

Origin and function of cartilage stem/progenitor cells in osteoarthritis

Progenitor Cells from Cartilage: Grade Specific Differences in Stem Cell Marker Expression

Perspectives on the Use of Stem Cells for Autism Treatment

Contact Info

Product

Resources

About